The New England Journal of Medicine published research results on Aug. 21 from a clinical trial of a drug shown to safely reduce the viral load and clinical illness of healthy adult volunteers intranasally infected with respiratory syncytial virus (RSV).
Le Bonheur Children’s Hospital has announced a new public giving campaign, Everyday Heroes, through which individuals or corporate partners can make a donation to help save lives through a gift to the hospital. To double the impact of the gifts, Le Bonheur is participating in the CN Miracle Match program.
A study published by JAMA Pediatrics – a leading, peer-reviewed journal of the American Medical Association – found that Nurse-Family Partnership® (NFP) reduces preventable death among both low-income mothers and their first-born children living in disadvantaged, urban neighborhoods.
Le Bonheur President and CEO Meri Armour was was one of four recipients of the Girls Incorporated 26th Annual Celebration Luncheon Awards. Armour received the SMART award, which celebrates women who have achieved significant academic success in their chosen field and/or have assisted others in reaching their academic goals – women who have achieved their personal, educational and career goals and are economically independent.
Asan Tejwani wants the people who work at Le Bonheur to know someone appreciates them. Tejwani recently made a gift to the hospital as a tribute to all Le Bonheur nurses, doctors and other medical professionals. An asthma treatment room in the Emergency Department was named in recognition of his special donation.
Complex heart imaging can increase cancer risks for children throughout their lifetime, according to a new study co-authored by Le Bonheur Cardiologist Jason Johnson, MD, MHS. The study, which appears in the June 9, 2014, issue of the American Heart Association’s journal Circulation, is the first in which researchers quantified cumulative radiation doses in pediatric heart patients and predicted lifetime cancer risks based on the types of exposures.
Researchers at Le Bonheur Children’s Hospital and the University of Tennessee Health Science Center announced results today from a clinical trial of a drug shown to safely reduce the viral load and clinical illness of healthy adult volunteers intranasally infected with respiratory syncytial virus (RSV).